|
FY2025
12 months to Sep 30, 2025
|
FY2023
12 months to Sep 30, 2023
|
|
|---|---|---|
| Revenue | ||
| Direct manufacturing costs | ||
| Gross margin | ||
| Expenses | ||
| Research and development | ||
| Government assistance (note 20) | ||
| Sales and marketing | ||
| General and administrative | ||
| Research and development | ||
| Government assistance | ||
| Sales and marketing | ||
| General and administrative | ||
| Stock based compensation | ||
| Depreciation and amortization | ||
| Operating expenses | ||
| Income from operations | ||
| Net finance charges (note 14) | ||
| Finance charges | ||
| Loss (gain) from fair value changes in derivative liability | ||
| Foreign exchange loss (gain) and interest income | ||
| Net loss before income taxes | ||
| Income (loss) before income tax | ||
| Income tax recovery | ||
| Net income (loss) for the year | ||
| Basic and Diluted loss per share | ||
| Outstanding, basic and fully diluted | ||
| Basic income (loss) per share | ||
| Diluted income (loss) per share | ||
| Weighted average number of shares – basic | ||
| Weighted average number of shares – diluted |
Loading...
